Before joining Alkermes, Dr. von Moltke was Vice President, Clinical and Exploratory Pharmacology at Sanofi/Genzyme Corporation ... College of Human Medicine, and she is a current member of the Board ...

These statements reflect the current estimates of Molecular Partners ... we did put on the 20 years Molecular Partners logo because it is our 20 years anniversary and it coincides with being ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only ...

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

The aim is to prepare for the onset of biosimilar competition in the 2030s to Sanofi’s current immunology blockbuster Dupixent (dupilumab), which is predicted to top $14 billion in sales this ...